ArticleVaccines2026

Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults.

Prabda Praphasiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.